Factors associated with psoriasis in a French Nationwide HIV cohort: the independent role of HLA-B*57:01.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
14
3
2020
medline:
9
3
2021
entrez:
14
3
2020
Statut:
ppublish
Résumé
Psoriasis is a T-cell-mediated inflammatory disease with genetic factors involved in its etiopathogenesis. In non-HIV populations, HLA-B57:01 has been associated with a higher risk of psoriasis. The aim of this study was to investigate demographic and immunovirological characteristics associated with psoriasis, and to assess whether HLA-B57:01 is associated with psoriasis among people living with HIV (PLHIV) followed in a large French multicenter Dat'AIDS cohort. All PLHIV followed up from January 2000 to December 2018 with an available result for HLA-B57:01 were included. Logistic regression models were used to identify associations between psoriasis (outcome variable) and explanatory variables. Among 31 076 PLHIV, the overall prevalence of psoriasis and HLA-B57:01 were 2.25 and 4.73%, respectively and varied according to ethnicity. By multivariate analysis, male gender [OR 1.81 (95% CI 1.46-2.24), P < 10], positive HLA-B57:01 [OR 2.66 (95% CI 2.12-3.33), P < 10], nadir CD4 cell count less than 200 cells/μl [OR 1.41 (95% CI 1.19-1.67), P < 10] and positive HCV serology [OR 1.45 (95% CI 1.20-1.76), P < 10] were significantly associated with a higher risk of psoriasis. Being born in West and Central Africa [OR 0.15 (95% CI 0.10-0.25), P < 10], the Caribbean islands [OR 0.14 (95% CI 0.05-0.45), P = 0.0008] or Latin America [OR 0.31 (95% CI 0.14-0.69), P = 0.004] was associated with a lower risk of psoriasis compared with patients born in mainland France. PLHIV carrying HLA-B57:01 have around a three-fold increased risk of psoriasis. This association might provide a possible explanation for the observed differences in psoriasis prevalence between ethnic groups.
Identifiants
pubmed: 32167971
doi: 10.1097/QAD.0000000000002519
pii: 00002030-202006010-00010
doi:
Substances chimiques
HLA-B Antigens
0
HLA-B57 antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1057-1063Références
Lebrun D, Hentzien M, Cuzin L, Rey D, Joly V, Cotte L, et al. the Dat’AIDS study groupEpidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort. AIDS 2017; 31:2159–2166.
Yen Y-F, Chuang P-H, Jen I-A, Chen M, Lan Y-C, Liu Y-L, et al. Incidence of autoimmune diseases in a nationwide HIV/AIDS patient cohort in Taiwan, 2000-2012. Ann Rheum Dis 2017; 76:661–665.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J J Eur Acad Dermatol Venereol 2017; 31:205–212.
Ceccarelli M, Venanzi Rullo E, Vaccaro M, Facciolà A, d’Aleo F, Paolucci IA, et al. HIV-associated psoriasis: epidemiology, pathogenesis, and management. Dermatol Ther 2019; 32:e12806.
Picciani BLS, Carneiro S, Sampaio ALB, Santos BM, Santos VCB, Gonzaga HFS, et al. A possible relationship of human leucocyte antigens with psoriasis vulgaris and geographic tongue. J Eur Acad Dermatol Venereol 2015; 29:865–874.
Feng B-J, Sun L-D, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P, et al. Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 2009; 5:e1000606.
Zhao YE, Ma JX, Hu L, Xiao SX, Zhao YL. Meta-analysis of the association between psoriasis and human leucocyte antigen-B. Br J Dermatol 2013; 169:417–427.
Lecuroux C, Saez-Cirion A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoel V, et al. Both HLA-B∗57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J Virol 2014; 88:176–187.
Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, et al. ECRIS integrated in the Spanish AIDS Research NetworkHLA-B∗57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clin Infect Dis 2016; 64:621–628.
Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, et al. Nadis GroupA large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009; 10:504–511.
Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J, et al. PREDICT-1 Study TeamHLA-B∗5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568–579.
Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L’Hénaff M, et al. 2013 French HIV expert groupFrench 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc 2014; 17:19034.
Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-α. Br J Dermatol 1991; 125:463–465.
Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 2005; 15:107–109.
Vejbaesya S, Eiermann TH, Suthipinititharm P, Bancha C, Stephens HA, Luangtrakool K. Chandanayingyong DSerological and molecular analysis of HLA class I and II alleles in Thai patients with psoriasis vulgaris. Tissue Antigens 1998; 52:389–392.
Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernández-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001; 62:1009–1030.
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al. High sensitivity of human leukocyte antigen–B∗5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46:1111–1118.
Sun H-Y, Hung C-C, Lin P-H, Chang S-F, Yang C-Y, Chang S-Y, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B∗5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 2007; 60:599–604.
Zucman D, Truchis Pde, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B∗5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquired Immune Deficiency Syndr 2007; 45:1–3.
Phillips EJ. Editorial commentary: genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?. Clin Infect Dis 2006; 43:103–105.
Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52:23–26.
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–385.
Mezzarobba M, Weill A, Sbidian E. Enquête épidémiologique en vie réelle des patients traités pour un psoriasis, en France à partir des données du SNDS. Annales de Dermatologie et de Vénéréologie 2018; 145:S107.
Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 2010; 10:470–478.
Yen Y-F, Jen I-A, Chen M, Lan Y-C, Lee C-Y, Chuang P-H, et al. HIV infection increases the risk of incident psoriasis: a nationwide population-based cohort study in Taiwan. J Acquir Immune Defic Syndr 2017; 75:493–499.
Imafuku S, Naito R, Nakayama J. Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol 2013; 40:813–818.
Cohen AD, Weitzman D, Birkenfeld S, Dreiher J. Psoriasis associated with hepatitis C but not with Hepatitis B. Dermatology 2010; 220:218–222.
Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure psoriasis area and severity index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol 2017; 18:583–590.
Prinz JC. Human leukocyte antigen-class i alleles and the autoreactive T cell response in psoriasis pathogenesis. Front Immunol 2018; 9:954.
Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, et al. Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57:727–739.
Nititham J, Gupta R, Zeng X, Hartogensis W, Nixon DF, Deeks SG, et al. Psoriasis risk SNPs and their association with HIV-1 control. Hum Immunol 2017; 78:179–184.
UK Collaborative HIV Cohort Study Steering CommitteeHLA B∗5701 status, disease progression, and response to antiretroviral therapy. AIDS 2013; 27:2587–2592.
Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, et al. Spontaneous control of HCV is associated with expression of HLA-B∗57 and preservation of targeted epitopes. Gastroenterology 2011; 140:686.e1–696.e1.
Chuang WC-M, Sarkodie F, Brown CJ, Owusu-Ofori S, Brown J, Li C, et al. Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. J Med Virol 2007; 79:724–733.